0
The FDA has approved once-daily levocetirizine dihydrochloride (Xyzal, UCB/Sanofi-Aventis), an antihistamine for the relief of symptoms associated with seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. The medication is indicated for adults and children six years of age and older.
The approval was based primarily on the results of eight randomized, placebo-controlled clinical trials involving more than 2,000 patients. Levocetirizine significantly reduced the severity of itching and the number and size of wheals. canada drugs pharmacy
Xyzal was first launched in Europe in 2001. The tablets are expected to be available in the U.S. during the 2007 fall allergy season.
